Valerio, Luca; Mavromanoli, Anna C.; Barco, Stefano et al.
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS studyEUROPEAN HEART JOURNAL. Bd. 43. H. 36. 2022 S. 3387-3398
Hetsch, Florian; Wang, Danni; Chen, Xufeng et al.
CKAMP44 controls synaptic function and strength of relay neurons during early development of the dorsal lateral geniculate nucleusJOURNAL OF PHYSIOLOGY-LONDON. Bd. 600. H. 15. 2022 S. 3549-3565
Schumann, Sven; Roesler, Mona K.; Schmeisser, Michael J.
Clinical anatomy of the frontal lobe and the insulaZEITSCHRIFT FUR EPILEPTOLOGIE. Bd. 35. H. 1. 2022 S. 8-12
Arnoldussen, Carsten W. K. P.; Notten, Pascale; Brans, Rutger et al.
Clinical impact of assessing thrombus age using magnetic resonance venography prior to catheter-directed thrombolysisEUROPEAN RADIOLOGY. Bd. 32. H. 7. 2022 S. 4555-4564
Langer, Florian; Gerlach, Horst E.; Schimke, Alexandra et al.
Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practiceTHROMBOSIS RESEARCH. Bd. 220. 2022 S. 145-152
Hobohm, Lukas; Sagoschen, Ingo; Habertheuer, Andreas et al.
Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolismRESUSCITATION. Bd. 170. 2022 S. 285-292
Hu, Yong; Scharrer, Anke; Hau, Chi et al.
Coagulation signaling from amniotic fluid to fetal skinBLOOD ADVANCES. Bd. 6. H. 19. 2022 S. 5538-5541
Sys, Stanislav; Weissbach, Stephan; Jakob, Lea et al.
CollembolAI, a macrophotography and computer vision workflow to digitize and characterize samples of soil invertebrate communities preserved in fluidMETHODS IN ECOLOGY AND EVOLUTION. Bd. 13. H. 12. 2022 S. 2729-2742
Mailer, Reiner K.; Renne, Thomas
Commentary on "Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa": Small molecule factor XIa inhibitor asundexian allows for safer anticoagulation COMMENTJOURNAL OF THROMBOSIS AND HAEMOSTASIS. Bd. 20. H. 6. 2022 S. 1309-1311
Pape, Katrin; Rolfes, Leoni; Steffen, Falk et al.
Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score-matched studyTHERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. Bd. 15. 2022